Ascentage Pharma Group International

Ascentage Pharma Group International is a global, integrated biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, primarily addressing unmet medical needs in oncology. The company's core strategy involves developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. Headquartered in Suzhou, China, Ascentage Pharma also maintains significant operations in Rockville, Maryland, USA.

The company's pipeline focuses on hematological malignancies, including chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). Key product candidates include Olverembatinib (HQP1351), the first and only third-generation BCR-ABL1 TKI approved in China for CML, and Lisaftoclax (APG-2575), a novel Bcl-2 inhibitor. Ascentage Pharma is recognized for its unique position as the only company globally with active clinical programs targeting all three known classes of key apoptosis regulators.

In recent developments, Ascentage Pharma reported a 162% increase in Q4 2025 revenue and a narrowed net loss, following its U.S. initial public offering in January 2025 and a significant share placing in 2025. The company continues to advance its clinical programs, with data from multiple trials, including those for Olverembatinib, Lisaftoclax, and Alrizomadlin, slated for presentation at the ASCO 2026 meeting. Dr. Dajun Yang serves as the co-founder, Chairman, and CEO, leading the company's strategic direction and research efforts. Olverembatinib and Lisaftoclax are commercialized in China, with Olverembatinib included in the China National Reimbursement Drug List.